Trial
NCT06400264
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Advanced Lymphoma
Intervention
Biopsy
Why stopped
No result will be reported- no patient accrued. Status Withdrawn: Study halted prematurely, prior to enrollment of first participant."
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-06